RNA interference targeting CHFR enhances taxol chemosensitivity in endometrial cancer cells

XIAOMAO LI*, XIAOYUN WANG*, YUEBO YANG, CHENGFANG XU and HUIMIN SHEN

Department of Obstetrics and Gynecology, The Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Road, 510630 Guangzhou, P.R. China

Received February 14, 2012; Accepted March 12, 2012

DOI: 10.3892/or.2012.1752

Abstract. In recent years, it has been reported that CHFR may be a useful biomarker for chemotherapeutic response to microtubule inhibitors in some tumor cells. The purpose of the present study was to test the hypothesis and to elucidate the underlying mechanism in endometrial cancer cells. First, we effectively inhibited CHFR expression at both the mRNA and protein levels using siRNA targeting the CHFR gene in Ishikawa and Hec-1a cells. We found that inhibition of CHFR expression significantly enhanced the cytotoxicity of taxol to both cell types, which was confirmed again by colony formation assays. Moreover, suppression of CHFR induced a significant increase of the mitotic index and much lower numbers of cells at the G2/M phase in both cells treated with taxol, indicating mitotic checkpoint impairment. On the other hand, the number of apoptotic cells significantly increased in Ishikawa and Hec-1a cells transfected with CHFR siRNA after treatment with taxol, which was associated with cyclin B1 nuclear localization. Our data indicate that RNA interference targeting CHFR can sensitize endometrial cancer cells to taxol and CHFR may be a promising molecular target to enhance the therapeutic effect of taxol for endometrial cancer.

Introduction

Endometrial cancer is the most common cancer of the female reproductive tract with 150,000 new cases diagnosed annually worldwide (1). Currently, there is no effective therapy for advanced and recurrent endometrial cancer. Taxol is a cornerstone in the treatment of this malignancy. Unfortunately, the efficacy of taxol is still limited by the development of drug resistance (2). Consequently, further studies that could enhance the therapeutic effect of taxol should be encouraged (3).

A novel mitotic checkpoint protein of significant interest in chemosensitizing activity of taxol is CHFR (checkpoint with forkhead-associated and ring finger), which is localized to chromosome 12q24.33 (4). In cellular response to mitotic stress by microtubule inhibitors, such as taxol, CHFR activation delays chromosome condensation during prophase and increases the ability of cells to survive the stress (5).

Some reports found that CHFR inactivation may play a key role in sensitivity of cancer cells to microtubule inhibitors by affecting mitotic checkpoint function (6-8). Moreover, we previously reported that CHFR suppression regulated by hypermethylation might sensitize endometrial cancer cells to taxol (9). Now we hypothesized that knockdown of CHFR in endometrial cancer cells would make them more sensitive to taxol. To test the hypothesis and elucidated the underlying mechanism, we employed the siRNA technique to silence CHFR expression. Then we determined whether taxol-mediated chemotherapy in combination with suppression of CHFR could be more effective in endometrial cancer cells.

Materials and methods

Cell culture. The human endometrial cancer cell lines, Ishikawa and Hec-1a, were obtained from American Type Culture Collection (Manassas, VA). All cells were maintained in Dulbecco's modified Eagle's medium (Gibco-BRL, Grand Island, NY) supplemented with 10% fetal bovine serum, under 5% CO2 at 37˚C.

Transfection of siRNA. Ishikawa and Hec-1a cells were transfected with CHFR siRNA or negative control siRNA (Shanghai GenePharma Co., China) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's directions. The optimal siRNA sequences for CHFR selection were: 5'-CGACAGCAGUCCAGUUAAdTdT3' (sense) and 3'-dTdT GCUGUCGUCAGGCUCUAU-5' (antisense). The negative-control siRNA sequences were: 5'-UUCUCCGAACGUGUCACGUTT-3' (sense) and 5'-ACGUGACACGUUCGGAGAATT-3' (antisense). Blank control (mock) cells were treated with Lipofectamine 2000 but not with siRNA. Cells were harvested 48 h after siRNA-treatment for the following analysis.

Quantitative real-time PCR. Total RNA from Ishikawa and Hec-1a was extracted with TRIzol reagent (Invitrogen). cDNA

*Contributed equally

Key words: endometrial cancer cells, CHFR, taxol, RNA interference
was then generated from 1.0 µg of total RNA with avian myeloblastosis virus reverse transcriptase (Takara, Otsu, Japan). Amplification was carried out with an ABI PRISM 7000 (Applied Biosystems, Tokyo, Japan) using SYBR green reagent for detection according to the protocol of SYBR Premix Ex Taq™ kit (Takara). Primer sequences for CHFR were 5'-CTGACACCTCGTTAGAGCATAC-3' (sense) and 5'-CTTCCTTACGATACTCTTCTTGGCA-3' (antisense); primer sequences for β-actin were 5'-TGACACCCAGCAATGAGA-3' (sense) and 5'-TCAAGTCATAGTCCGCCTAGAAGCA-3' (antisense). The comparative threshold method was used to calculate the relative amount of mRNA of treated sample in comparison with control samples (10).

**Western blot analysis.** The cells were harvested, lysed and centrifuged at 15,000 rpm for 5 min at 4°C. Protein content in the supernatants was determined by a BCA protein assay kit. Equal amounts of protein were separated by 10% SDS-PAGE, transferred onto PVDF membranes and then incubated with CHFR (1:500, Santa Cruz, USA), β-actin (1:2000, Santa Cruz, USA) antibody overnight at 4°C. After incubation with secondary antibody (KPL, Gaithersburg, MD), membrane was treated with ECL-Western blot detecting reagent (Amersham Biosciences, USA) antibody overnight at 4˚C. After incubation with 3% BSA and 0.1% Triton X-100 in PBS for 30 min. Cells were incubated for overnight at 4˚C with cyclin B1 antibody (1:500, Santa Cruz). Secondary antibody conjugated to Alexa Fluor 488 (1:200, Molecular Probes) was then used. Nuclei were detected using Quantity One software (Bio-Rad Laboratories, Hercules, CA). The density measurement was correlated to protein expression and normalized to β-actin.

**Cell cytotoxicity assay.** The cells (5,000 cells/well) seeded in 96-well plates were transfected with 50 nM siRNA for 48 h. Transfected and untransfected cells were incubated with fresh medium containing various concentrations of taxol for another 24 h. Cell viability was assayed by a tetrazolium salt (WST-8)-based colorimetric assay according to the manufacturer's instructions (Roche, Basel, Switzerland). Cells were incubated in 96-well microplates with 10 µl of 50% WST-8 solution for 5 h at 37°C. In each well, 100 µl of dimethyl sulfoxide was added to dissolve the formazan crystals, and the optical density was measured. The results were expressed as mean ± SD. Statistical analysis was performed by one-way ANOVA or Student's t-test. P<0.05 was considered statistically significant.

**Results**

**Inhibition of CHFR expression by siRNA.** To test the silencing effect of siRNA targeting CHFR gene, real-time PCR and western blotting were performed to detect the expression of CHFR mRNA and protein in two endometrial cancer cell lines, Ishikawa and Hec-1a. Compared with mock or control-siRNA cells, the relative expression level of CHFR mRNA was reduced by 70% in Ishikawa CHFR-siRNA cells and 75% in Hec-1a CHFR-siRNA cells (p<0.05; Fig. 1A). CHFR expression at the protein level was significantly inhibited in both cells, which was consistent with the mRNA level (p<0.01; Fig. 1B). There was no obvious difference between mock and control-siRNA cells (p>0.05). These results indicated that CHFR expression was significantly suppressed by CHFR siRNA in Ishikawa and Hec-1a cells.

**Suppression of CHFR sensitized endometrial cancer cells to taxol.** Previous studies suggested that CHFR might be involved in chemoresistance to microtubule inhibitors in many cancer types (6). To test this idea, we addressed whether suppression of CHFR could enhance sensitivity of taxol in two endometrial cancer cell lines. Forty-eight hours after transfection of siRNA, cells were exposed to various concentrations of taxol for 24 h. When CHFR expression was decreased in the cells, we observed that the cytotoxicity significantly increased by
CHFR siRNA as compared with mock or control siRNA. After treatment with taxol at a final concentration of 1.0 µg/ml for 24 h, cytotoxicity increased to 67±5.1% in Ishikawa CHFR-siRNA cells (compared with 27.6±3% in control-siRNA cells) and 89.2±5.7% in HeC-1a CHFR-siRNA cells (compared with 39.4±2.8% in control-siRNA cells) (p<0.05; Fig. 2A), indicating a significantly increased sensitivity to taxol by suppression of CHFR expression.

The increased sensitivity of endometrial cancer cells with CHFR suppression to taxol was confirmed again by subsequent colony formation assay. Fourteen days after exposure to taxol (1 µg/ml) for 24 h, both CHFR-siRNA cell types exhibited much smaller colony diameter, and their colony formation numbers were reduced by 80%-90%, compared with controls (p<0.05; Fig. 2B).

Knockdown of CHFR induced mitotic checkpoint impairment and entry of cells to mitosis when treated with taxol. Cancer cells lacking CHFR show mitotic checkpoint impairment when treated with microtubule inhibitors (7). We evaluated the impaired checkpoint function in endometrial cancer cells with CHFR suppression after treatment with taxol, using mitotic index. Exposed to taxol (1 µg/ml) for 24 h, the CHFR-siRNA cells (Ishikawa and HeC-1a) showed condensed chromosomes and higher mitotic indexes than control-siRNA cells. Especially in HeC-1a CHFR-siRNA cells, the mitotic index was 87±3.5%, compared with 6±1.4% in control-siRNA cells (p<0.01; Fig. 3A), indicating that knockdown of CHFR led to mitotic checkpoint impairment after treatment with taxol.

As a cell cycle checkpoint gene, CHFR induces cell cycle arrest in G2 phase (G2 arrest) to allow repair of damaged DNA during mitotic stress (8). When Ishikawa and HeC-1a cells (expressing CHFR) were incubated for 24 h with taxol (1 µg/ml), large numbers of cells remained at G2/M phase (30-35%) with normal checkpoint function. In contrast, both CHFR-siRNA cells (lack CHFR) showed a decrease in the number of cells at G2/M phase (6-9%) after treatment with taxol for 24 h (Fig. 3B), indicating that due to mitotic checkpoint impairment, CHFR suppression may induce endometrial cancer cells to enter mitosis but not arrest in prophase when treated with taxol.

More apoptosis induced by CHFR suppression was associated with cyclin B1 nuclear localization. In this study, we also determined apoptosis of endometrial cancer cells with CHFR
LI et al: CHFR SUPPRESSION ENHANCES TAXOL RESPONSE

suppression after treatment with taxol, using flow cytometric analysis. We found that the apoptotic rate was increased from 4.04±0.87% in Ishikawa mock cells to 17.65±1.8% in Ishikawa CHFR-siRNA cells, and from 6.89±1% in Hec-1a mock cells to 20.45±1.76% in Hec-1a CHFR-siRNA cells (p<0.05; Fig. 4). It showed that inhibition of CHFR could promote apoptosis of endometrial cancer cells when treated with taxol.

On the other hand, it was reported that cyclin B1 accumulated in the cytoplasm between S and G2 phase, and then localized in the nuclei during prophase (11). Localization of cyclin B1 is among the factors determining the cellular decision to undergo apoptosis in response to DNA damage (12). Thus, we examined the distribution of cyclin B1 after treating endometrial cancer cells with taxol. When Ishikawa and Hec-1a cells transfected with negative or mock siRNA were treated with taxol, cyclin B1 mainly localized in the cytoplasm. By contrast, in CHFR-siRNA cells treated with taxol, cyclin B1 mainly accumulated in the nuclei (Fig. 5). The results suggest that the greater amount of apoptosis induced by CHFR suppression, which impelled endometrial cancer cells to enter into mitosis without repair of genotoxic damage when treated with taxol, may be correlated with cyclin B1 translocation to the nuclei.

Discussion
Advanced and recurrent endometrial cancer remain major clinical problems by causing considerable morbidity and mortality in women worldwide. Apart from the standard approaches, novel
In the past 10 years, CHFR as a mitotic checkpoint has gained more and more attention as a possible novel biomarker for chemotherapeutic response to microtubule inhibitors (taxol) in human cancers (15). RNA interference is a mechanism of post-transcriptional gene silencing. Small interfering RNA (siRNA) has served as a powerful technology to knock down the expression of target genes (16). Current studies and clinical trials demonstrate that manipulation of the RNAi mechanism by use of targeted siRNA offers a novel and attractive therapeutic option against cancer (17). There are reports showing that silencing of the IKKε gene by siRNA inhibited invasiveness and growth of breast cancer cells (18) and siRNAs targeting the individual CK2 subunits enhanced chemosensitivity to gemcitabine in human pancreatic cancer cells (19). In our study, the siRNA technology was applied to suppress CHFR expression.

Previously, we had demonstrated that CHFR suppression regulated by hypermethylation might sensitize endometrial cancer cells to taxol (9). Among 6 endometrial cancer cell lines, Ishikawa and Hec-1a cells with high CHFR expression were resistant to taxol. Therefore, we chose these two cell lines in our present study.

First, we effectively inhibited CHFR expression by using siRNA targeting CHFR gene in Ishikawa and Hec-1a cells. Then, we found that inhibition of CHFR expression significantly enhanced the cytotoxicity of taxol in both endometrial cancer cells. The enhancement of taxol cytotoxicity to Ishikawa and

Figure 3. Knockdown of CHFR induces mitotic checkpoint impairment and entry of cells to mitosis when treated with taxol. (A) Transfected cells after treatment of taxol (1.0 µg/ml) for 24 h were stained with Hoechst-33342 and then nuclei were observed under a fluorescent microscope using a blue filter (x400). White arrows indicate mitotic cells. The mitotic cells showed condensed chromosomes. Data are presented as mean ± SD (n=3). *p<0.05; **p<0.01. (B) Incubation for 24 h with taxol (1 µg/ml), transfected cells were stained with propidium iodide and analyzed by flow cytometry. Data are representative of 3 independent experiments.
LI et al: CHFR SUPPRESSION ENHANCES TAXOL RESPONSE

Figure 4. CHFR suppression induced higher numbers of apoptotic cells. Transfected cells after treatment with taxol (1 µg/ml) were stained with Annexin-V+PI and analyzed by flow cytometry. Data are presented as mean ± SD (n=3). *p<0.05.

Figure 5. CHFR suppression induces cyclin B1 accumulation in the nuclei during mitotic stress. When CHFR-expressing Ishikawa and Hec-1a cells were treated with taxol, cyclin B1 mainly localized in the cytoplasm. In contrast, treating CHFR-siRNA cells with taxol, cyclinB1 accumulated in the nuclei. The results presented are an average of 6 random microscopic fields from 3 independent experiments.
Hec-1a cells transfected with CHFR siRNA was confirmed again by colony formation assays. The results highlight the potential of utilizing CHFR as a molecular target for cancer therapy.

CHFR regulates an early mitotic checkpoint, during prophase, in response to the disruption of normal microtubule formation or stabilization as assessed after treatment with microtubule inhibitors such as taxol (20). The CHFR-mediated prophase checkpoint is typically monitored by calculating the mitotic index of cells treated with microtubule inhibitors (21). In our study, suppression of CHFR induced condensed chromosomes and an obvious increase of the mitotic index during mitotic stress in Ishikawa and Hec-1a cells treated with taxol. Much lower numbers of cells at G2/M phase were seen among cells transfected with CHFR siRNA than mock or negative control cells. On the other hand, the number of apoptotic cells significantly increased in CHFR siRNA cells after treatment with taxol. It was because knockdown of CHFR impaired the function of mitotic checkpoint, and cells lacking CHFR apparently did not stop at prophase and entered mitosis when treated with microtubule inhibitors, which triggered apoptosis. It may help to elucidate why sensitivity of taxol was enhanced in endometrial cancer cells when CHFR expression was silenced.

Our results showed that inhibition of CHFR could promote apoptosis of endometrial cancer cells when treated with taxol. However, the molecular mechanism of apoptosis promoted by CHFR suppression during mitotic stress has not yet been confirmed. Activation of cyclin B1 and its translocation to the nuclei is another important step for cells entering mitosis (22,23) and precedes apoptosis induced by microtubule inhibitors (24,25). In our study, the nuclear localization of cyclin B1 was possibly associated with apoptosis of cells induced by CHFR suppression. Our results were consistent with several reports showing that nuclear localization of cyclin B1 correlates with sensitivity of cancer cells to chemotherapeutic drugs (7). In endometrial cancer cells during mitotic stress, apoptosis promoted by CHFR suppression, which impelled entry into mitosis without repair of DNA damage, may be related with cyclin B1 accumulation in the nuclei. However, the mechanism by which nuclear localization of cyclin B1 triggers apoptotic signaling remains to be answered in the future research.

In conclusion, CHFR can be efficiently suppressed by siRNA. Moreover, our data verified the hypothesis that suppression of CHFR expression by siRNA sensitizes endometrial cancer cells to taxol. Taken together, our study supported the application of CHFR-targeted therapies for endometrial cancer. We believe that RNA interference targeting CHFR could represent novel strategies for enhancing the sensitivity of cancer cells to taxol.

Acknowledgements

This study was supported by the grants from Endometrial Cancer Program of Guangdong Province, Science and Technology Development Fund of Macau (no. 002/2009/A), Science and Technology Plan Project of Guangdong Province (no. 2009B060700028, no. 2010B031600035) and National Natural Science Foundation of China (no. 30772332).

References